TNF RII/TNFRSF1B Antibody (22221) [Unconjugated]

Human peripheral blood granulocytes were stained with Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB226, filled histogram) or isotype control antibody (MAB003, open histogram) followed by anti-mouse IgG PE-conjugated secondary antibody (F0101B). View our protocol for Staining Membrane-associated Proteins.

TNF RII/TNFRSF1B was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB226) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Recombinant Human TNF RII/TNFRSF1B inhibits Recombinant Human TNF‑ alpha (Catalog # 210-TA) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of Recombinant Human TNF‑ alpha (0.25 ng/mL) activity elicited by Recombinant Human TNF RII/TNFRSF1B (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB226). The ND50 is typically 0.5-1.5 µg/mL in the presence of the metabolic inhibitor actinomycin D (1 µg/mL).

U937 cells were stained with Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB226, filled histogram) or isotype control antibody (Catalog # MAB003, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgM Secondary Antibody (Catalog # F0116). View our protocol for Staining Membrane-associated Proteins.

Representative immunohistochemical staining for TNFR1 and TNFR2 in the kidneys.(A) Images were captured at 200× (a, b, c, d, i, j, k, l) and 100× (e, f, g, h, m, n, o, p) magnification. Images show the negative controls in the glomeruli (a, i) and tubulointerstitium (e, m) and TNFR1 and TNFR2 immunostaining in the glomeruli (b, j) and tubulointerstitium (f, n) of the normal kidneys, respectively. TNFR1 and TNFR2 immunostaining is shown in the glomeruli (c, k) and tubulointerstitium (g, o) of the kidneys from selected IgAN patients who had levels of serum TNFR2 that ranked in the lowest 10 [low group (LG)]. TNFR1 and TNFR2 immunostaining in the glomeruli (d, l) and tubulointerstitium (h, p) of the kidneys from selected IgAN patients who had levels of serum TNFR2 that ranked in the highest 10 [high group (HG)], respectively, are also shown. (B) Percentage of the TNFR1 and TNFR2-positive area in the kidneys were evaluated. Glomerular and tubulointerstitial TNFR expression was elevated significantly in IgAN patients compared with those in control (Ctrl) subjects. The tubulointerstitial TNFR2-positive area was significantly larger in HG than in LG. However, there was no significant difference in the tubulointerstitial TNFR1 and glomerular TNFR areas between LG and HG. * P < 0.01, **P < 0.001, †P < 0.0001. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0122212), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: Flow, B/N, ICC/IF
• Clone: 22221
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TNF RII/TNFRSF1B Antibody (22221) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human TNF RII
  Leu23-Asp257
  Accession # P20333
• Specificity: Detects human TNF RII/TNFRSF1B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) 4‑1BB, rhCD27, rhCD30, rhCD40, rhDR3, rhDR6, rhFas, rhGITR, rhHVEM, rhLTR beta , rhNGF R, rhOPG, rhRANK, rhTNF RI, or recombinant mouse TNF RII is observed. Neutralizes the biological effect of rhTNF RII but not rhTNF RI.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF1B
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunocytochemistry 8-25 ug/mL
  • Neutralization 0.5-1.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TNF RII/TNFRSF1B Antibody (22221) [Unconjugated]

• CD120b antigen
• CD120b
• Etanercept
• p75 TNF receptor
• p75TBPII
• p75TNFR
• soluble TNFR1B variant 1
• TNF RII
• TNFBRp80 TNF-alpha receptor
• TNF-R2
• TNFR2TNFR1B
• TNF-R75
• TNFR80
• TNFRII
• TNF-RII
• TNF-R-II
• TNFR-II
• TNFRSF1B
• tumor necrosis factor beta receptor
• tumor necrosis factor binding protein 2
• Tumor necrosis factor receptor 2
• tumor necrosis factor receptor superfamily member 1B
• tumor necrosis factor receptor superfamily, member 1B
• Tumor necrosis factor receptor type II

Background

TNF RII, also known as p75 or p80 TNF R, is a prototypic member of the TNF receptor superfamily and has been designated TNFRSF1B. It binds TNF with highaffinity and is expressed primarily in cells of the immune system.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TNF RII/TNFRSF1B Antibody (MAB226)(20)

Publications using MAB226

• CA Sander, EA Rush, J Shi, LMRB Arantes, RJ Tesi, MA Ross, MJ Calderon, SC Watkins, JM Kirkwood, RL Ferris, LH Butterfiel, L Vujanovic Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors Journal of Translational Medicine, 2022-07-25;20(1):331. 2022-07-25 [PMID: 35879777] (ICC, Human)
• Belinda Carrión, Yawei Liu, Mahdieh Hadi, Jon Lundstrom, Jeppe Romme Christensen, Cecilie Ammitzbøll et al. Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis Neurology - Neuroimmunology Neuroinflammation 11/1/2021 [PMID: 34385365]
• John R. Bradley, Jun Wang, Simon Pacey, Anne Y. Warren, Jordan S. Pober, Rafia S. Al‐Lamki Tumor necrosis factor receptor‐2 signaling pathways promote survival of cancer stem‐like CD133 + cells in clear cell renal carcinoma FASEB BioAdvances 2/1/2020 [PMID: 32123862]
• Chen-Fang Chung, Thomas Kitzler, Nadezda Kachurina, Katarina Pessina, Sima Babayeva, Martin Bitzan et al. Intrinsic tumor necrosis factor-alpha pathway is activated in a subset of patients with focal segmental glomerulosclerosis PLOS ONE 2019-05-16 [PMID: 31095586] (Neutralization, Human)
• Chen-Fang Chung, Thomas Kitzler, Nadezda Kachurina, Katarina Pessina, Sima Babayeva, Martin Bitzan et al. Intrinsic tumor necrosis factor-alpha pathway is activated in a subset of patients with focal segmental glomerulosclerosis PLOS ONE 5/16/2019 [PMID: 31095586]
• M Monguió-To, M Franquesa, MR Sarrias, FE Borràs Low doses of LPS exacerbate the inflammatory response and trigger death on TLR3-primed human monocytes Cell Death Dis, 2018-05-01;9(5):499. 2018-05-01 [PMID: 29717111] (Neutralization, Human)
• Xiaoliang Wang, Zhaoyue He, He Liu, Shida Yousefi, Hans-Uwe Simon Neutrophil Necroptosis Is Triggered by Ligation of Adhesion Molecules following GM-CSF Priming The Journal of Immunology 11/15/2016 [PMID: 27815445]
• Rafia S Al-Lamki, Jun Wang, Jun Yang, Natalie Burrows, Patrick H Maxwell, Timothy Eisen et al. Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma Oncotarget 4/26/2016 [PMID: 26992212]
• Nadezda Kachurina, Chen-Fang Chung, Erin Benderoff, Sima Babayeva, Martin Bitzan, Paul Goodyer et al. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis American Journal of Physiology-Renal Physiology 2016-05-15 [PMID: 26719363] (Neutralization, Human)
• Nadezda Kachurina, Chen-Fang Chung, Erin Benderoff, Sima Babayeva, Martin Bitzan, Paul Goodyer et al. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis American Journal of Physiology-Renal Physiology 5/15/2016 [PMID: 26719363]
• Sonoda Y, Gohda T, Suzuki Y, Omote K, Ishizaka M, Matsuoka J, Tomino Y Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS ONE, 2015-04-10;10(4):e0122212. 2015-04-10 [PMID: 25860248] (IHC, Human)
• Claudia Esser, Anna Bachmann, Daniela Kuhn, Kathrin Schuldt, Birgit Förster, Meike Thiel et al. Evidence of promiscuous endothelial binding by P lasmodium falciparum ‐infected erythrocytes Cellular Microbiology 5/1/2014 [PMID: 24444337]
• Nomura T, Aoyama M, Waguri-Nagaya Y, Goto Y, Suzuki M, Miyazawa K, Asai K, Goto S Tumor necrosis factor stimulates osteoclastogenesis from human bone marrow cells under hypoxic conditions. Exp Cell Res, 2013-12-17;321(2):167-77. 2013-12-17 [PMID: 24360989] (Neutralization, Human)
• Raquel Espín, Francisco J. Roca, Sergio Candel, María P. Sepulcre, Juan M. González-Rosa, Francisca Alcaraz-Pérez et al. TNF receptors regulate vascular homeostasis in zebrafish through a caspase-8, caspase-2 and P53 apoptotic program that bypasses caspase-3 Disease Models & Mechanisms 9/8/2012 [PMID: 22956347]
• Raquel Espín, Francisco J. Roca, Sergio Candel, María P. Sepulcre, Juan M. González-Rosa, Francisca Alcaraz-Pérez et al. TNF receptors regulate vascular homeostasis in zebrafish through a caspase-8, caspase-2 and P53 apoptotic program that bypasses caspase-3 Disease Models & Mechanisms 2012-09-08 [PMID: 22956347] (Neutralization, Human)
• Ding B, Kirkiles-Smith NC, Pober JS FOXO3a regulates oxygen-responsive expression of tumor necrosis factor receptor 2 in human dermal microvascular endothelial cells. J. Biol. Chem., 2009-05-27;284(29):19331-9. 2009-05-27 [PMID: 19473970] (ICC, Western Blot, Human)
• van Mierlo GJ, Scherer HU, Hameetman M, Morgan ME, Flierman R, Huizinga TW, Toes RE Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J. Immunol., 2008-03-01;180(5):2747-51. 2008-03-01 [PMID: 18292492] (Flow Cytometry, Human)
• Ebert EC, Mehta V Human intestinal intraepithelial lymphocytes keep TNF alpha levels low by cell uptake and feedback inhibition of transcription. Cell. Immunol., 2006-08-17;241(1):7-13. 2006-08-17 [PMID: 16914126] (Neutralization, Human)
• Hadjadj S, Cloutier I, Geoffroy P, Tanguay JF Stent implantation in coronary porcine arteries is associated with early activation of TNFalpha and TNFalpha receptor II expression. Atherosclerosis, 2006-07-20;192(1):25-32. 2006-07-20 [PMID: 16857205] (IHC-P, Porcine)
• Chopin V, Slomianny C, Hondermarck H, Le Bourhis X Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors&#039; signaling and requires P21(waf1). Exp. Cell Res., 2004-08-15;298(2):560-73. 2004-08-15 [PMID: 15265702] (Western Blot, Human)

Bioinformatics

• Gene Symbol: TNFRSF1B
• Uniprot:
  • P20333()